ITUS

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch ITUS and buy or sell other stocks, ETFs, and their options commission-free!

About ITUS

Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology. It operates through the following segments: Cancer Vaccines, CAR-T Therapeutics, and Other. 

CEO
Amit D. Kumar, PhD, MBA
CEOAmit D. Kumar, PhD, MBA
Employees
Employees
Headquarters
San Jose, California
HeadquartersSan Jose, California
Founded
1982
Founded1982
Employees
Employees

ITUS Key Statistics

Market cap
99.47M
Market cap99.47M
Price-Earnings ratio
-8.85
Price-Earnings ratio-8.85
Dividend yield
Dividend yield
Average volume
112.97K
Average volume112.97K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$5.46
52 Week high$5.46
52 Week low
$2.33
52 Week low$2.33

Stock Snapshot

As of today, ITUS(ITUS) shares are valued at $2.93. The company's market cap stands at 99.47M, with a P/E ratio of -8.85.

On 2026-03-10, ITUS(ITUS) shares started trading at —, with intraday highs of — and lows of —.

Trading volume for ITUS(ITUS) stock has reached 0, versus its average volume of 112.97K.

Over the past 52 weeks, ITUS(ITUS) stock has traded between a high of $5.46 and a low of $2.33.

Over the past 52 weeks, ITUS(ITUS) stock has traded between a high of $5.46 and a low of $2.33.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.